Ozempic vs Wegovy: the same drug, two brands
Ozempic and Wegovy are both semaglutide, made by Novo Nordisk and injected once a week. They differ in what they are approved for, the doses they reach, and, as a result, in who pays for them. Here is what that means if you have a prescription for either.
Updated October 4, 2026
At a glance
- Approved for
- Ozempic
- Type 2 diabetes, including lowering heart and kidney risks in people with diabetes
- Wegovy
- Chronic weight management, and lowering heart attack and stroke risk in adults with obesity and heart disease
- Highest maintenance dose
- Ozempic
- 2 mg once a week
- Wegovy
- 2.4 mg once a week
- Forms
- Ozempic
- Weekly pen; the oral diabetes version is sold as Rybelsus
- Wegovy
- Weekly pen, and a daily tablet approved in December 2025
- Usual payer
- Ozempic
- Insurance, which commonly covers it for type 2 diabetes
- Wegovy
- Varies: plans differ on weight-management coverage, and many people pay themselves
Ozempic semaglutide for type 2 diabetes | Wegovy semaglutide for weight management | |
|---|---|---|
| Approved for | Type 2 diabetes, including lowering heart and kidney risks in people with diabetes | Chronic weight management, and lowering heart attack and stroke risk in adults with obesity and heart disease |
| Highest maintenance dose | 2 mg once a week | 2.4 mg once a week |
| Forms | Weekly pen; the oral diabetes version is sold as Rybelsus | Weekly pen, and a daily tablet approved in December 2025 |
| Usual payer | Insurance, which commonly covers it for type 2 diabetes | Varies: plans differ on weight-management coverage, and many people pay themselves |
Why one molecule has two brands
Novo Nordisk developed semaglutide for diabetes first, then tested higher doses for weight loss and sought separate approval. The pens are not interchangeable: the dose steps differ, so moving from one to the other needs a new prescription and a plan from the prescriber. Using Ozempic off-label for weight loss is legal for a prescriber, but plans generally cover it only for diabetes.
Cost and coverage
Neither has a generic, so a pharmacy’s cash price for either pen sits close to list price. Novo Nordisk sells both directly to self-paying patients through NovoCare at prices set by dose, and those programs, or insurance with a savings card, usually cost less than a pharmacy’s cash price for the brand. Medicare Part D covers Ozempic for diabetes; eligible enrollees can get Wegovy through the Medicare GLP-1 bridge program until the end of 2027, and Medicare-negotiated prices for the semaglutide family take effect in January 2027.
Side effects
The same: nausea, diarrhea, vomiting and constipation, mostly while the dose is rising; the same boxed warning about thyroid C-cell tumors in rodents; and the same warnings about pancreatitis and gallbladder problems. Higher doses of Wegovy bring somewhat more stomach side effects.
Questions for your prescriber
- Which brand matches the reason I am taking it?
- Will my plan cover it for that reason?
- If I switch from one to the other, what dose do I start on?
Already have a prescription?
Upload it and licensed pharmacies respond with their own cash price. You choose, and pay the pharmacy.
Read more
Sources
- DailyMed, FDA-approved prescribing information
- CMS, Medicare drug price negotiation
- MedlinePlus drug information (National Library of Medicine)
Written by the Script Unlock editorial team from the sources above. It is general information, not advice for you or your pet; your prescriber decides which medicine is right.
Script Unlock is a marketplace that lets licensed pharmacies quote a cash price on your prescription. It does not prescribe, dispense or sell medication, does not process patient payments, and does not give medical advice. Always follow the instructions of your prescriber and pharmacist and read the medication guide supplied with your medicine.